Rachel Suflita McKee

Cambridge, Mass. (November 7, 2023) – Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that the Company will be participating in the Jefferies London Healthcare Conference taking place November 14-16, 2023.

The Remix management team will be hosting one-on-one meetings with investors on Tuesday, November 14. For those investors interested in scheduling a meeting with the Remix team, please contact your Jefferies representative.

About Remix Therapeutics

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster technology platform facilitates RNA processing pattern identification, leveraging these learnings to modulate gene expression. Remix’s innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.

Contacts:

Media Contact:
Lissette Steele
lsteele@vergescientific.com
202-930-4762 ext. 409

Investor Contact:
Will O’Connor  
Stern Investor Relations 
will.oconnor@sternir.com  
212-362-1200

Cambridge, Mass. (September 5, 2023) – Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that management will participate in several upcoming investor conferences:

  • Citi 2023 18th Annual BioPharma Conference on September 7, 2023 in Boston, MA
  • Morgan Stanley 21st Annual Global Healthcare Conference on September 11, 2023 in New York, NY
  • UBS Biotechnology Private Company Virtual Symposium 2023 on September 20, 2023


The Remix management team will be hosting one-on-one meetings with investors at each conference. For those investors interested in scheduling a meeting with the Remix team, please contact your Citi, Morgan Stanley or UBS representative.

About Remix Therapeutics
Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster technology platform facilitates RNA processing pattern identification, leveraging these learnings to modulate gene expression. Remix’s innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.

Contacts:
Media Contact:
Lissette Steele
lsteele@vergescientific.com
202-930-4762 ext. 409

Investor Contact:
Will O’Connor  
Stern Investor Relations 
will.oconnor@sternir.com  
212-362-1200

Cambridge, Mass. (May 25, 2023) – Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 12:30 p.m. ET in New York.

The Remix management team will be hosting one-on-one meetings with investors on Thursday, June 8. For those investors interested in scheduling a meeting with the Remix team, please contact your Jefferies representative.

About Remix Therapeutics
Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster technology platform
facilitates RNA processing pattern identification, leveraging these learnings to modulate gene expression. Remix’s innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.

Contacts:
Media Contact:
Lissette Steele
lsteele@vergescientific.com
202-930-4762 ext. 409


Investor Contact:
Will O’Connor  
Stern Investor Relations 
will.oconnor@sternir.com  
212-362-1200

Experienced Biotech Executive Brings More Than 20 Years of Financial Leadership

Cambridge, Mass. (March 22, 2023) – Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of Robert Gagnon as Chief Financial Officer.

“We are delighted to have Rob joining Remix as he brings a wealth of experience to the CFO role. His combination of financial acumen and tenure in the life science industry makes him an ideal fit,” said Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix Therapeutics.  “Rob is a great addition to our strong management team of industry veterans with deep domain expertise. His experience in all areas of biopharmaceutical finance, including his ability to grow organizations successfully and track record with public companies, will be invaluable as we advance our REMaster technology platform to bring innovative therapies to fight diseases with unmet need.” 

“I am truly excited to be joining Remix as we have a unique opportunity to change the course of various diseases with a novel platform approach that modulates RNA processing to address those diseases at their origins,” said Mr. Gagnon. “I look forward to working with my colleagues to build Remix into a leading biopharmaceutical company transforming the way we treat diseases.”

Mr. Gagnon brings more than 20 years of financial and commercial experience leading global finance operations. Prior to his appointment, he served as Chief Financial Officer and Operating Partner at Gurnet Point Capital, a healthcare venture capital and private equity fund. Mr. Gagnon has also held executive and financial leadership roles at numerous public and private biotechnology companies, including Verastem Oncology, Harvard Bioscience, Inc., Clean Harbors, Inc., and Biogen Idec, Inc. He has also worked in a variety of senior positions at Deloitte & Touche, LLP, and Price Waterhouse Coopers, LLP. He holds an M.B.A. from the MIT Sloan School of Management and a B.A. in Accounting from Bentley College.

Mr. Gagnon currently serves on the Board of Directors at Verastem Oncology and Purple Biotech.

About Remix Therapeutics

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster technology platform facilitates RNA processing pattern identification, leveraging these learnings to modulate gene expression. Remix’s innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.

Contacts:

Media Contact:
Lissette Steele
lsteele@vergescientific.com
202-930-4762 ext. 409

Investor Contact:
Will O’Connor  
Stern Investor Relations 
will.oconnor@sternir.com  
212-362-1200